000096230 001__ 96230
000096230 005__ 20210902121915.0
000096230 0247_ $$2doi$$a10.22203/eCM.v040a06
000096230 0248_ $$2sideral$$a120544
000096230 037__ $$aART-2020-120544
000096230 041__ $$aeng
000096230 100__ $$aFernandez-Pernas, P.
000096230 245__ $$aMesenchymal stromal cells for articular cartilage repair: preclinical studies
000096230 260__ $$c2020
000096230 5060_ $$aAccess copy available to the general public$$fUnrestricted
000096230 5203_ $$aRheumatic diseases such as osteoarthritis (OA) are a major social and economic burden because of the population aging and the lack of curative solutions. An effective cell therapy may be the best treatment option for OA and other cartilage diseases. However, the main cellular strategy used to repair articular cartilage, the transplantation of autologous chondrocytes, is limited to a small number of patients with traumatic lesions. The use of joint replacement after years of disease progression proves the great medical need in current practice. Mesenchymal stromal/stem cells (MSCs) provide an alternative cell source for cartilage regeneration due to numerous advantages, comprising relative ease to isolate and culture, chondrogenic capacity, and anti-inflammatory effects. Initial clinical trials with MSCs have led to encouraging results, but many variables have to be considered to attain true amelioration of disease or repair (type and status of cartilage disease, source and conditions of cells, administration regime, combinatorial approaches). Particularly, allogeneic MSCs are an advantageous cellular product. The animal models chosen for preclinical evaluation are also relevant for successful translation into clinical practice. Considering the limitations in the field, rigorous comparative and validating studies in well-established animal models (including large animals) are still needed to set up the bases for additional clinical trials. The present review of studies performed in small and large animal models should help clarify the applicability of MSC-based therapies for articular cartilage repair.
000096230 536__ $$9info:eu-repo/grantAgreement/EUR/ERDF/A way to build Europe$$9info:eu-repo/grantAgreement/ES/MINECO/AGL2017-84411-P
000096230 540__ $$9info:eu-repo/semantics/openAccess$$aby-sa$$uhttp://creativecommons.org/licenses/by-sa/3.0/es/
000096230 590__ $$a3.942$$b2020
000096230 591__ $$aORTHOPEDICS$$b16 / 82 = 0.195$$c2020$$dQ1$$eT1
000096230 591__ $$aENGINEERING, BIOMEDICAL$$b30 / 90 = 0.333$$c2020$$dQ2$$eT2
000096230 591__ $$aMATERIALS SCIENCE, BIOMATERIALS$$b20 / 40 = 0.5$$c2020$$dQ2$$eT2
000096230 591__ $$aCELL & TISSUE ENGINEERING$$b18 / 29 = 0.621$$c2020$$dQ3$$eT2
000096230 592__ $$a1.066$$b2020
000096230 593__ $$aBiochemistry$$c2020$$dQ1
000096230 593__ $$aBioengineering$$c2020$$dQ1
000096230 593__ $$aMedicine (miscellaneous)$$c2020$$dQ1
000096230 593__ $$aBiomedical Engineering$$c2020$$dQ1
000096230 593__ $$aCell Biology$$c2020$$dQ1
000096230 593__ $$aBiomaterials$$c2020$$dQ1
000096230 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000096230 700__ $$0(orcid)0000-0001-9818-508X$$aBarrachina, L.$$uUniversidad de Zaragoza
000096230 700__ $$aMarquina, M.
000096230 700__ $$0(orcid)0000-0003-3289-2675$$aRodellar, C.$$uUniversidad de Zaragoza
000096230 700__ $$aArufe, M.C.
000096230 700__ $$aCosta, C.
000096230 7102_ $$11001$$2420$$aUniversidad de Zaragoza$$bDpto. Anatom.,Embri.Genét.Ani.$$cÁrea Genética
000096230 773__ $$g40 (2020), 88-114$$pEur. cells mater.$$tEUROPEAN CELLS & MATERIALS$$x1473-2262
000096230 8564_ $$s699234$$uhttps://zaguan.unizar.es/record/96230/files/texto_completo.pdf$$yVersión publicada
000096230 8564_ $$s499985$$uhttps://zaguan.unizar.es/record/96230/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000096230 909CO $$ooai:zaguan.unizar.es:96230$$particulos$$pdriver
000096230 951__ $$a2021-09-02-10:44:51
000096230 980__ $$aARTICLE